Global Life Sciences M&A: Market Overview and Trends

Sean Geraghty’s experience includes mergers and acquisitions (both public and private, for corporate clients and private equity clients), IPOs (on the Official List, AIM and overseas), secondary offerings, joint ventures and general corporate matters. Mr. Geraghty has acted for major European and international corporate clients and financial institutions on substantial transactions.

David Rosenthal, co-chair of Dechert’s Global Corporate Finance and Capital Markets Practice and co-lead of the firm's Life Sciences Practice, represents publicly and privately held corporations, investment banks, and venture capital firms focused on the life sciences and medical device, technology, media, and other growth sectors. He represents clients in corporate finance transactions, mergers and acquisitions, joint ventures, licensings and strategic alliances.

Gregory A. Schernecke focuses his practice on mergers and acquisitions, with a particular emphasis on private equity; corporate finance and general corporate matters. Mr. Schernecke represents private equity sponsors, alternative asset managers and operating companies in complex merger and acquisition transactions across a wide range of industry sectors, including life sciences and healthcare.